3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Interventions
pembrolizumab
44
Specimen Handling
41
Carboplatin
31
Magnetic Resonance Spectroscopy
28
Cyclophosphamide
26
Biopsy
26
Nivolumab
22
fludarabine
21
Dexamethasone
19
Gemcitabine
18
Bevacizumab
16
atezolizumab
14
Pemetrexed
14
Paclitaxel
14
Docetaxel
13
Cisplatin
13
Rituximab
12
Temozolomide
11
Ipilimumab
11
venetoclax
10
Injections
10
X-Rays
9
Prednisone
9
Oxaliplatin
9
Fulvestrant
9
Fluorouracil
9
Vincristine
8
Trastuzumab
8
Radiotherapy
8
Lenalidomide
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Histamine Antagonists
×
30 days
×
Clear all
NCT05319730
2026-05-26
MK-3475-06B
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
230 enrolled